These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

330 related items for PubMed ID: 17174468

  • 1. A patient with neuro-Behçet's disease is successfully treated with etanercept: further evidence for the value of TNFalpha blockade.
    Alty JE, Monaghan TM, Bamford JM.
    Clin Neurol Neurosurg; 2007 Apr; 109(3):279-81. PubMed ID: 17174468
    [Abstract] [Full Text] [Related]

  • 2. [Behçet's disease and the possibilities of modern tumour necrosis factor inhibiting medication].
    van Laar JA, Jamnitski A, Baarsma GS, van Daele PL, van Hagen PM.
    Ned Tijdschr Geneeskd; 2006 Apr 01; 150(13):705-9. PubMed ID: 16623340
    [Abstract] [Full Text] [Related]

  • 3. A case of mucocutaneous Behçet's disease responding to etanercept.
    Sommer A, Altmeyer P, Kreuter A.
    J Am Acad Dermatol; 2005 Apr 01; 52(4):717-9. PubMed ID: 15793540
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Behçet's syndrome: from aetiology to treatment.
    Powell RJ.
    Adv Exp Med Biol; 2003 Apr 01; 528():481-6. PubMed ID: 12918749
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Successful treatment of long-standing neuro-Behçet's disease with infliximab.
    Sarwar H, McGrath H, Espinoza LR.
    J Rheumatol; 2005 Jan 01; 32(1):181-3. PubMed ID: 15630746
    [Abstract] [Full Text] [Related]

  • 10. Short-term trial of etanercept in Behçet's disease: a double blind, placebo controlled study.
    Melikoglu M, Fresko I, Mat C, Ozyazgan Y, Gogus F, Yurdakul S, Hamuryudan V, Yazici H.
    J Rheumatol; 2005 Jan 01; 32(1):98-105. PubMed ID: 15630733
    [Abstract] [Full Text] [Related]

  • 11. The utility of tumour necrosis factor blockade in orphan diseases.
    Keystone EC.
    Ann Rheum Dis; 2004 Nov 01; 63 Suppl 2(Suppl 2):ii79-ii83. PubMed ID: 15479879
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. A young girl with refractory intestinal Behçet's disease: a case report and review of literatures on pediatric cases who received an anti-tumor necrosis factor agent.
    Watanabe S, Aizawa-Yashiro T, Tsuruga K, Kinjo M, Ito E, Tanaka H.
    Rheumatol Int; 2013 Dec 01; 33(12):3105-8. PubMed ID: 23266507
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. The use of biologic agents in the treatment of ocular manifestations of Behcet's disease.
    Benitah NR, Sobrin L, Papaliodis GN.
    Semin Ophthalmol; 2011 Dec 01; 26(4-5):295-303. PubMed ID: 21958178
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.